WallStSmart

Merck & Company Inc (MRK)vsProfound Medical Corp (PROF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 349469% more annual revenue ($65.77B vs $18.81M). MRK leads profitability with a 13.6% profit margin vs -206.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PROF

Avoid

26

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -2.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.60

$39.64 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for PROF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PROF2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
103.6%10/10

Revenue surging 103.6% year-over-year

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PROF4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$237.65M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-65.7%2/10

ROE of -65.7% — below average capital efficiency

Free Cash FlowQuality
$-8.58M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PROF

The strongest argument for PROF centers on Revenue Growth, Debt/Equity. Revenue growth of 103.6% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PROF

The primary concerns for PROF are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while PROF is a hypergrowth play — different risk/reward profiles.

PROF carries more volatility with a beta of 0.52 — expect wider price swings.

PROF is growing revenue faster at 103.6% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Profound Medical Corp

HEALTHCARE · MEDICAL DEVICES · USA

Profound Medical Corp. The company is headquartered in Mississauga, Canada.

Visit Website →

Want to dig deeper into these stocks?